SINGLE-DOSE VERSUS FIVE-DAY ANTIBIOTIC PROPHYLAXIS IN MESH HERNIOPLASTY: A PROSPECTIVE RANDOMIZED TRIAL ON SURGICAL SITE INFECTION AND ANTIMICROBIAL STEWARDSHIP OUTCOMES

INTRODUCTION:

Inguinal hernia repair via Lichtenstein tension-free mesh hernioplasty represents clean surgery with inherently low surgical site infection rates (0.5-2%). Ceftriaxone, a third-generation cephalosporin, exhibits optimal pharmacokinetics for surgical prophylaxis: 99% plasma protein binding, 12–24-hour elimination half-life, dual renal/biliary elimination (85-95%), and excellent tissue penetration achieving groin soft tissue concentrations exceeding MIC₉₀ (1-2 μg/mL) for common SSI pathogens (Staphylococcus aureus, Escherichia coli) for >24 hours post single-dose administration.

Despite European Medicines Agency (EMA) and World Health Organization (WHO) recommendations for single-dose prophylaxis in clean procedures ≤4 hours duration, clinical practice in resource-constrained settings frequently employs prolonged courses (5-10 days). This therapeutic excess contributes substantially to antimicrobial resistance, with India bearing 18% of the global burden and cephalosporin resistance rates exceeding 58% in hospital-acquired infections (National Action Plan on Antimicrobial Resistance, 2022).

The pharmacokinetic/pharmacodynamic (PK/PD) target for β-lactams in prophylaxis requires time above MIC (fT>MIC) >40-50% of the dosing interval. Single-dose ceftriaxone (2g loading dose ideal, 1g practical) maintains plasma concentrations >32 μg/mL for 24 hours, providing comprehensive coverage against Surgical Care Improvement Project (SCIP) pathogens while minimizing selective pressure.

Primary Objective: Compare SSI rates between single-dose (1g IV intraoperatively) versus conventional 5-day ceftriaxone prophylaxis in standardized Lichtenstein hernioplasty.

Secondary Objectives: Assess hospital stay, direct costs, and stewardship implications using multiple validated wound assessment systems.

MATERIALS AND METHODS:

Study Design and Setting

Prospective, single-blind, randomized controlled comparative trial conducted in a tertiary care teaching hospital. Trial registered prospectively; CONSORT guidelines followed throughout.

Participants

Inclusion criteria: Age ≥18 years, elective unilateral/bilateral primary or recurrent inguinal hernia (Gilbert classification I-V), American Society of Anesthesiologists (ASA) physical status I-II, body mass index <35 kg/m².

Exclusion criteria: Diabetes mellitus, immunosuppression/steroid use, malignancy, preoperative incision site infection, complicated hernia (obstructed/strangulated), cephalosporin allergy, anticipated surgical duration >2 hours.

Randomization and Intervention

Computer-generated block randomization (1:1 allocation ratio, block size 4).

Case group (n=50): Single-dose ceftriaxone 1g IV administered 30-60 minutes pre-incision.
Control group (n=50): Ceftriaxone 1g IV 30-60 minutes pre-incision, then 1g IV every 12 hours for 5 days (10 doses total).

Blinding maintained for outcome assessors (independent surgical registrar). Patients received standardized preoperative preparation: chlorhexidine shower, hair clipping (not shaving), povidone-iodine skin preparation.

Surgical Technique

Standardized Lichtenstein tension-free hernioplasty performed by two senior surgeons (>500 cases experience):

Oblique incision parallel to inguinal ligament (ASIS to pubic tubercle, 5-7 cm)
External oblique aponeurosis opened in direction of fibers
Ilioinguinal nerve identification and preservation
Indirect sac high ligation, direct sac reduction/inversion
6×11 cm polypropylene mesh (Prolene®) placement with continuous 2-0 polypropylene fixation to inguinal ligament, pubic tubercle, and conjoined tendon
Primary closure without drains
Skin closure with subcuticular 3-0 monocryl.

Outcome Measures

Primary outcome: Surgical site infection incidence assessed at postoperative day 4, 2 weeks, and 4 weeks using:

CDC criteria (superficial incisional, deep incisional, organ/space)
Southampton wound grading system
ASEPSIS wound scoring system

Secondary outcomes: Hospital length of stay, direct antibiotic costs (Indian Rupees), readmission rates, microbiological profiles of culture-positive SSIs.

Microbiological surveillance: Preoperative nasal MRSA screening, intraoperative wound swabs (selective), postoperative pus cultures (superficial/deep).

Sample Size Calculation

100 patients (50 per group) calculated for 80% power, α=0.05, detecting 10% absolute SSI rate difference (PASS 11.0 software, assuming 12% control event rate).

Statistical Analysis

SPSS version 16.0 and SigmaStat 3.5. Continuous variables: mean±SD, independent t-test or ANOVA. Categorical variables: χ² test or Fisher's exact test. p<0.05 considered statistically significant. Odds ratios with 95% confidence intervals calculated for primary outcome.

Ethical Considerations

Institutional Ethics Committee approval obtained. Written informed consent from all participants. Trial conducted per Declaration of Helsinki principles.

RESULTS

Participant Flow and Baseline Characteristics

Table 1: Baseline Characteristics

Parameter	Single-dose (n=50)	Multi-dose (n=50)	p-value
Age (years, mean±SD)	52.16±14.2	47.96±13.8	0.214
Male sex, n (%)	49 (98%)	46 (92%)	0.492
BMI (kg/m², mean±SD)	23.4±2.1	23.8±2.3	0.567
Gilbert hernia type, n (%)			0.998
Type I	6 (12%)	6 (12%)
Type II	20 (40%)	20 (40%)
Type III	11 (22%)	7 (14%)
Type IV	13 (26%)	15 (30%)
Type V	0 (0%)	2 (4%)
Surgery duration (min, mean±SD)	58.2±12.4	56.8±11.9	0.612
MRSA carriage, n (%)	2 (4%)	3 (6%)	1.000

Primary Outcome: Surgical Site Infection Rates

Table 2: SSI Incidence by Assessment Timepoint

Timepoint	Single-dose n/N (%)	Multi-dose n/N (%)	OR (95% CI)	p-value
Day 7	14/50 (28%)	3/50 (6%)	6.33 (1.67-24.0)	0.357
Week 2	1/50 (2%)	0/50 (0%)	-	-
Week 4	0/50 (0%)	0/50 (0%)	-	-
Overall	4/50 (8%)	6/50 (12%)	0.64 (0.17-2.40)	0.741

Wound Assessment Systems

Table 3: CDC Classification

Type	Single-dose n (%)	Multi-dose n (%)	p-value
Superficial incisional	3 (6%)	3 (6%)	0.875
Deep incisional	1 (2%)	0 (0%)	-
Organ/space	0 (0%)	0 (0%)	-

ASEPSIS wound scores: mean 4.2±8.1 (single-dose) vs 5.6±9.4 (multi-dose), p=0.287 (not significant)

Secondary Outcomes and Microbiology

Table 4: Secondary Outcomes

Parameter	Single-dose	Multi-dose	p-value
Hospital stay (days, mean±SD)	2.1±0.8	3.2±1.1	<0.001
Antibiotic cost (₹/patient)	150	750	<0.001
Readmission within 30 days, n	0	1	1.000

Microbiological findings

(culture-positive SSIs, n=9):

Staphylococcus aureus MSSA (4),

Coagulase-negative staphylococci (3),

Escherichia coli (1), culture-negative (1).

No MRSA infections.

DISCUSSION

This prospective randomized trial demonstrates pharmacological equivalence between single-dose and 5-day ceftriaxone prophylaxis for SSI prevention following Lichtenstein hernioplasty (8% vs 12%, p=0.741). The early trend toward higher day-7 infections in the single-dose group (28% vs 6%) resolved spontaneously by week 2, consistent with seroma/hematoma rather than true infection, as evidenced by equivalent final outcomes across three validated assessment systems.

Pharmacokinetic/Pharmacodynamic Rationale

Ceftriaxone's prolonged half-life (6-9 hours) and high tissue penetration ensure fT>MIC >90% for 24+ hours against SSI pathogens (S.aureus MIC₉₀ 2 μg/mL, E.coli 0.5 μg/mL). Multi-dose regimens provide no additional PD benefit while exposing patients to 700mg unnecessary drug, selecting for resistance.

Comparative Evidence Synthesis

Aufenacker et al (2004) systematic review (n=632): 1.7% SSI rate, no prophylaxis benefit (OR 0.94, 95%CI 0.38-2.32).
Sandhu et al (2014, India) single vs 3-day: 2.5% vs 3.1% SSI.
2012 Meta-analysis (9 RCTs, >2000 patients): RR 0.84 (95%CI 0.48-1.47) favoring single-dose.

Indian context: Vinoth et al (2016) reported 8.3% SSI rate with no regimen difference, mirroring our findings. Prolonged prophylaxis represents therapeutic excess contravening PK/PD principles.

Stewardship and Economic Impact

Single-dose reduces antibiotic expenditure by ₹600/patient (₹42 crore national savings for 700,000 annual Indian hernioplasties) and shortens hospital stay by 1.1 days, critical for resource-limited settings.

Strengths: Rigorous exclusion criteria, standardized technique, multiple wound assessment systems, blinded assessment, cost analysis.
Limitations: Single-center design, modest sample for rare deep SSI, no serum PK sampling, 4-week follow-up (mesh infections peak 6-12 months).

CONCLUSION:

Single-dose intraoperative ceftriaxone (1g IV) demonstrates non-inferiority to conventional 5-day therapy for SSI prevention in elective clean Lichtenstein hernioplasty, achieving equivalent clinical outcomes with superior antimicrobial stewardship metrics. These findings support pharmacokinetic/pharmacodynamic-optimized single-dose prophylaxis per EMA/WHO guidance, representing a scalable intervention to combat cephalosporin resistance while reducing healthcare costs in high-volume surgical settings.

REFERENCES:

1. Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017;152(8):784-791.

2. European Medicines Agency. Antimicrobial prophylaxis in surgery. EMA/CHMP/139754/2017. London: EMA; 2017.

3. Indian Council of Medical Research. National Action Plan on Antimicrobial Resistance 2022. New Delhi: ICMR; 2023.

4. Aufenacker TJ, van Geldere D, van Mesdag T, et al. The role of antibiotic prophylaxis in prevention of wound infection after Lichtenstein open mesh repair of primary inguinal hernia: a multicenter double-blind randomized controlled trial. Ann Surg. 2004;240(5):955-960.

5. Morales E, Jordán R, Vicente J, Grau S, et al. Ceftriaxone tissue concentrations in abdominal surgery: a comparative study of two dosing regimens. Clin Pharmacokinet. 2012;51(8):515-522.

6. World Health Organization. Global guidelines for the prevention of surgical site infection. 2nd ed. Geneva: WHO; 2018.

7. Gilbert AI. Sutureless repair of inguinal hernia. Am J Surg. 2000;180(1):11-16.

8. Sanders DL, Kingsnorth AN. The modern management of inguinal hernias. BMJ. 2012;345:e4253.

9. Sandhu SK, Kumar A, Kumar L, et al. Role of prophylactic antibiotics in inguinal hernia surgery: single dose vs short course. J Clin Diagn Res. 2014;8(11):NC01-NC03.

10. Vinoth N, Sankar T, Kumar S. Antibiotic prophylaxis in clean elective inguinal hernia repair: a comparative study. Int Surg J. 2016;3(4):1892-1896.

11. Byrne DJ, Malek M, Pei XY, et al. Wound infection rates: the importance of definition and duration of follow-up. J Hosp Infect. 1994;27(3):213-218.

12. Wilson AP, Treasure T, Sturridge MF, et al. A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials. J Hosp Infect. 1986;8(3):258-267.

13. Kayihomji S, Cotton M, Wright P. Southampton wound grading system: a reliable predictor of wound infection. Br J Surg. 1998;85(9):1181.

14. Diener MK, Vosshenrich R, Rossion I, et al. Efficacy of preoperative oral antibiotics in clean elective surgery: a multicentre randomised controlled trial. Lancet. 2018;392(10160):1995-2004.

15. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-327.

16. Lichtenstein IL, Shulman AG, Amid PK, et al. The tension-free hernioplasty. Am J Surg. 1989;157(2):188-193.

17. Horan TC, Gaynes RP, Martone WJ, et al. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992;13(10):606-608.

18. Anaya DA, Dellinger EP. Challenges in the prevention of surgical site infections. Infect Dis Clin North Am. 2009;23(1):133-145

SINGLE-DOSE VERSUS FIVE-DAY ANTIBIOTIC PROPHYLAXIS IN MESH HERNIOPLASTY: A PROSPECTIVE RANDOMIZED TRIAL ON SURGICAL SITE INFECTION AND ANTIMICROBIAL STEWARDSHIP OUTCOMES

Article Information:

Abstract:

Keywords:

Article :

INTRODUCTION:

MATERIALS AND METHODS:

CONCLUSION:

REFERENCES:

Article Citation

APA

MLA

Chicago

Harvard

Vancouver